184 related articles for article (PubMed ID: 38058206)
1. Real-world experience of baricitinib in atopic dermatitis: including add-on therapy for patients using dupilumab.
Lim JH; Kwon SH; Lew BL
Int J Dermatol; 2024 Feb; 63(2):196-200. PubMed ID: 38058206
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study.
Liu B; Song X; Liao S; Luan T; Zhao Z
Int Arch Allergy Immunol; 2023; 184(10):966-974. PubMed ID: 37245505
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
[TBL] [Abstract][Full Text] [Related]
4. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
[TBL] [Abstract][Full Text] [Related]
5. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
Wollenberg A; Simon D; Kulthanan K; Figueras-Nart I; Misery L; Tangsirisap N; Spina L; Lu N; Grond S; Eyerich K
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):695-702. PubMed ID: 38041556
[TBL] [Abstract][Full Text] [Related]
6. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Silverberg JI; Simpson EL; Wollenberg A; Bissonnette R; Kabashima K; DeLozier AM; Sun L; Cardillo T; Nunes FP; Reich K
JAMA Dermatol; 2021 Jun; 157(6):691-699. PubMed ID: 33978711
[TBL] [Abstract][Full Text] [Related]
7. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
9. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
10. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
Rosmarin D; Fretzin S; Strowd L; Casillas M; DeLozier AM; Dawson Z; Chen S; Lu N; Thyssen JP
J Cutan Med Surg; 2022; 26(4):377-385. PubMed ID: 35354410
[TBL] [Abstract][Full Text] [Related]
11. Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2022 May; 23(3):409-420. PubMed ID: 35503162
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
Reich K; DeLozier AM; Nunes FP; Thyssen JP; Eichenfield LF; Wollenberg A; Ross Terres JA; Watts SD; Chen YF; Simpson EL; Silverberg JI
J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective.
Johansson E; Giovannitti M; Mezzetti M; Lu N; Sabatino S
J Med Econ; 2023; 26(1):1155-1166. PubMed ID: 37674383
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
Torrelo A; Rewerska B; Galimberti M; Paller A; Yang CY; Prakash A; Zhu D; Pontes Filho MAG; Wu WS; Eichenfield LF
Br J Dermatol; 2023 Jul; 189(1):23-32. PubMed ID: 36999560
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
17. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
Rosmarin D; Casillas M; Chen S; Dawson Z; Pierce E; Zhang H; Bukhalo M; Smith S
J Cutan Med Surg; 2022; 26(3):262-266. PubMed ID: 35086348
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
[TBL] [Abstract][Full Text] [Related]
19. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
Drucker AM; Lam M; Elsawi R; Prieto-Merino D; Malek R; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
Br J Dermatol; 2024 Jan; 190(2):184-190. PubMed ID: 37831594
[TBL] [Abstract][Full Text] [Related]
20. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]